Study Title
A Phase II Study of Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design
Study Details
Description:
A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design
Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Contacts:
Arndt Vogel, Prof. Dr.vogel.arndt@mh-hannover.de
+49 511 5326 ext 760
Johanna Riedel, Dr.riedel.johanna@ikf-khnw.de
+49 7601 ext 4635
Government Study Link:
NCT04522544 - Click here to see study onClinicalTrials.gov